查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1588313

脊椎生物製剂市场规模、份额、趋势分析报告：按产品、按手术、按最终用途、按地区、细分市场预测，2025-2030 年

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix), By Surgery, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

脊椎生物製剂市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球脊椎生物製剂市场规模预计将达到43.8亿美元，2025年至2030年复合年增长率为4.9%。

这个市场主要是由脊椎损伤发生率的增加所推动的。在已开发国家和低度开发国家，脊椎畸形的盛行率都在上升，导致手术数量增加。这对脊椎生物製品市场产生了积极影响。

除此之外，人们越来越认识到生物製药在脊椎融合手术中的许多好处，例如最大限度地缩短术后时间和激活细胞增殖的能力，也推动了市场的发展。生物材料和移植骨替代物越来越多地被用作脊椎畸形的治疗选择。由于患有脊椎疾病的老年人口比例不断增加以及越来越多地采用这些产品作为治疗方法，预计脊椎生物製剂市场在预测期内将扩大。

老年人更容易出现椎间滑脱和椎间盘退化。除此之外，道路事故和运动伤害导致的创伤病例数量不断增加，也推动了对脊椎生物製剂的需求。根据 2018 年出版的《开放取用微创手术日誌》(MIS)，微创技术正在被用来治疗多种脊椎疾病。在美国，每年约有 40 万例手术病例，脊椎融合手术已被认为是针对脊椎创伤、退化性疾病、肿瘤和结构异常最常用和最成熟的治疗方法之一。

脊椎生物製剂市场亮点

  • 脊椎植入物细分市场占据主导地位，2024 年占全球销售额的 58.7%。这种优越性归因于与使用同种异体移植物相关的许多优点。
  • 到 2024 年，医院细分市场将占据市场主导地位。该领域的主要驱动力是在这些设施中进行的脊椎融合手术数量不断增加。
  • 北美占据市场主导地位，2024 年市占率为 48.2%。市场的成长归因于稳定的经济成长、微创手术的日益普及以及椎间盘相关问题、脊椎狭窄和脊椎椎间滑脱等脊椎疾病盛行率的上升。
  • 由于患者人数众多以及患者和外科医生对生物製药益处的认识不断提高，预计亚太地区的市场将出现快速增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章脊椎生物製剂市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章脊椎生物製品市场：产品业务分析

  • 2024年及2030年产品市场占有率
  • 产品细分仪表板
  • 2018-2030 年按产品分類的市场规模、预测与趋势分析
  • 同种异体脊椎移植物
  • 骨移植替代物
  • 基于细胞的矩阵

第五章脊椎生物製品市场：外科业务分析

  • 2024年及2030年手术市场占有率
  • 手术细分仪表板
  • 2018-2030 年按手术分類的市场规模、预测与趋势分析
  • 前路颈切除术切除融合术（ACDF）
  • 椎间腰椎椎间融合(TLIF)
  • 后侧椎间融合术（PLIF）
  • 前路腰椎融合术（ALIF）
  • 侧向腰椎椎间融合(LLIF)

第六章脊椎生物製品市场：最终用途业务分析

  • 2024 年及 2030 年最终用途市场占有率
  • 最终用途细分仪表板
  • 2018-2030 年按最终用途分類的市场规模、预测与趋势分析
  • 医院
  • 门诊设施

第七章脊椎生物製剂市场：按产品分類的区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章脊椎生物製品市场：手术区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章脊椎生物製剂市场：按最终用途分類的区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第10章竞争格局

  • 参与企业概况
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Stryker
    • NuVasive, Inc.
    • Orthofix
    • DePuy Synthes（Johnson &Johnson）
    • Exactech, Inc.
    • Zimmer Biomet
Product Code: GVR-3-68038-588-5

Spine Biologics Market Growth & Trends:

The global spine biologics market size is estimated to reach USD 4.38 billion by 2030, expanding at a CAGR of 4.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

Spine Biologics Market Report Highlights:

  • The spinal allografts segment dominated the market and accounted for 58.7% of the global revenue in 2024. This dominance can be attributed to the numerous benefits associated with the usage of allografts.
  • The hospital segment dominated the market in 2024. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.
  • North America dominated the market and accounted for a 48.2% share in 2024. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.
  • Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Surgery
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Spine Biologics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Spine Biologics Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 4.4. Spinal Allografts
    • 4.4.1. Spinal Allografts Market, 2018 - 2030 (USD Billion)
      • 4.4.1.1. Machined Bones Allograft Market, 2018 - 2030 (USD Billion)
      • 4.4.1.2. Demineralized Bone Matrix Market, 2018 - 2030 (USD Billion)
  • 4.5. Bone Graft Substitutes
    • 4.5.1. Bone Graft Substitutes Market, 2018 - 2030 (USD Billion)
      • 4.5.1.1. Bone Morphogenetic Proteins Market, 2018 - 2030 (USD Billion)
      • 4.5.1.2. Synthetic Bone Grafts Market, 2018 - 2030 (USD Billion)
  • 4.6. Cell-based Matrix
    • 4.6.1. Cell-based Matrix Market, 2018 - 2030 (USD Billion)

Chapter 5. Spine Biologics Market: Surgery Business Analysis

  • 5.1. Surgery Market Share, 2024 & 2030
  • 5.2. Surgery Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Surgery, 2018 to 2030 (USD Billion)
  • 5.4. Anterior Cervical Discectomy and Fusion (ACDF)
    • 5.4.1. Anterior Cervical Discectomy and Fusion (ACDF) Market, 2018 - 2030 (USD Billion)
  • 5.5. Transforaminal Lumbar Interbody Fusion (TLIF)
    • 5.5.1. Transforaminal Lumbar Interbody Fusion (TLIF) Market, 2018 - 2030 (USD Billion)
  • 5.6. Posterior Lumbar Interbody Fusion (PLIF)
    • 5.6.1. Posterior Lumbar Interbody Fusion (PLIF) Market, 2018 - 2030 (USD Billion)
  • 5.7. Anterior Lumbar Interbody Fusion (ALIF)
    • 5.7.1. Anterior Lumbar Interbody Fusion (ALIF) Market, 2018 - 2030 (USD Billion)
  • 5.8. Lateral Lumbar Interbody Fusion (LLIF)
    • 5.8.1. Lateral Lumbar Interbody Fusion (LLIF) Market, 2018 - 2030 (USD Billion)

Chapter 6. Spine Biologics Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 6.5. Outpatient Facilities
    • 6.5.1. Outpatient Facilities Market, 2018 - 2030 (USD Billion)

Chapter 7. Spine Biologics Market: Regional Estimates & Trend Analysis by Product

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Spine Biologics Market: Regional Estimates & Trend Analysis by Surgery

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8. MEA
    • 8.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Spine Biologics Market: Regional Estimates & Trend Analysis by End Use

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.4. North America
    • 9.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Regulatory Framework
      • 9.4.2.3. Competitive Insights
      • 9.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Regulatory Framework
      • 9.4.3.3. Competitive Insights
      • 9.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Regulatory Framework
      • 9.4.4.3. Competitive Insights
      • 9.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5. Europe
    • 9.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Regulatory Framework
      • 9.5.2.3. Competitive Insights
      • 9.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Regulatory Framework
      • 9.5.3.3. Competitive Insights
      • 9.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Regulatory Framework
      • 9.5.4.3. Competitive Insights
      • 9.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Regulatory Framework
      • 9.5.5.3. Competitive Insights
      • 9.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Regulatory Framework
      • 9.5.6.3. Competitive Insights
      • 9.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.7. Norway
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Regulatory Framework
      • 9.5.7.3. Competitive Insights
      • 9.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.8. Denmark
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Regulatory Framework
      • 9.5.8.3. Competitive Insights
      • 9.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.9. Sweden
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Regulatory Framework
      • 9.5.9.3. Competitive Insights
      • 9.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Regulatory Framework
      • 9.6.2.3. Competitive Insights
      • 9.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Regulatory Framework
      • 9.6.3.3. Competitive Insights
      • 9.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Regulatory Framework
      • 9.6.4.3. Competitive Insights
      • 9.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.5. South Korea
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Regulatory Framework
      • 9.6.5.3. Competitive Insights
      • 9.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.6. Australia
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Regulatory Framework
      • 9.6.6.3. Competitive Insights
      • 9.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Regulatory Framework
      • 9.6.7.3. Competitive Insights
      • 9.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7. Latin America
    • 9.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Regulatory Framework
      • 9.7.2.3. Competitive Insights
      • 9.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Regulatory Framework
      • 9.7.3.3. Competitive Insights
      • 9.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8. MEA
    • 9.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Regulatory Framework
      • 9.8.2.3. Competitive Insights
      • 9.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Regulatory Framework
      • 9.8.3.3. Competitive Insights
      • 9.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Regulatory Framework
      • 9.8.4.3. Competitive Insights
      • 9.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Regulatory Framework
      • 9.8.5.3. Competitive Insights
      • 9.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Stryker
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. NuVasive, Inc.
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Orthofix
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. DePuy Synthes (Johnson & Johnson)
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Exactech, Inc.
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Zimmer Biomet
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global spine biologics market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 5. Global spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 6. Global spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 7. North America spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 8. North America spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 9. North America spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 10. North America spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 11. U.S. spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 12. U.S. spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 13. U.S. spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 14. Canada spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 15. Canada spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 16. Canada spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 17. Mexico spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 18. Mexico spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 19. Mexico spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 20. Europe spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Europe spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 22. Europe spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 23. Europe spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 24. UK spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 25. UK spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 26. UK spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 27. Germany spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 28. Germany spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 29. Germany spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 30. France spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 31. France spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 32. France spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 33. Italy spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 34. Italy spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 35. Italy spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 36. Spain spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 37. Spain spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 38. Spain spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 39. Norway spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 40. Norway spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 41. Norway spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 42. Denmark spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 43. Denmark spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 44. Denmark spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 45. Sweden spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 46. Sweden spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 47. Sweden spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 48. Asia Pacific spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 49. Asia Pacific spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 50. Asia Pacific spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 51. Asia Pacific spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 52. Japan spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 53. Japan spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 54. Japan spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 55. China spine biologics market, by product, 2018-2030 (USD Billion)
  • Table 56. China spine biologics market, by surgery, 2018-2030 (USD Billion)
  • Table 57. China spine biologics market, by end-use, 2018-2030 (USD Billion)
  • Table 58. India spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 59. India spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 60. India spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 61. Australia spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 62. Australia spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 63. Australia spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 64. South Korea spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 65. South Korea spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 66. South Korea spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 67. Thailand spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 68. Thailand spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 69. Thailand spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 70. Latin America spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 71. Latin America spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 72. Latin America spine biologics market, by surgery, 2018 - 2030 (USD Billion
  • Table 73. Latin America spine biologics market, by end-use, 2018 - 2030 (USD Billion
  • Table 74. Brazil spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 75. Brazil spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 76. Brazil spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 77. Argentina spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 78. Argentina spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 79. Argentina spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 80. Middle East & Africa spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 81. Middle East & Africa spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 82. Middle East & Africa spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 83. Middle East & Africa spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 84. South Africa spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 85. South Africa spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 86. South Africa spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 87. Saudi Arabia spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 88. Saudi Arabia spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 89. Saudi Arabia spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 90. UAE spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 91. UAE spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 92. UAE spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 93. Kuwait spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 94. Kuwait spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 95. Kuwait spine biologics market, by end-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Spine biologics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product outlook (USD Billion)
  • Fig. 10 Transportation mode outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 Spine biologics market dynamics
  • Fig. 13 Spine biologics market: Porter's five forces analysis
  • Fig. 14 Spine biologics market: PESTLE analysis
  • Fig. 15 Spine biologics market: Product segment dashboard
  • Fig. 16 Spine biologics market: Product market share analysis, 2024 & 2030
  • Fig. 17 Spinal allografts market, 2018 - 2030 (USD Billion)
  • Fig. 18 Bone graft substitutes market, 2018 - 2030 (USD Billion)
  • Fig. 19 Cell-based matrix market, 2018 - 2030 (USD Billion)
  • Fig. 20 Spine biologics market: Surgery segment dashboard
  • Fig. 21 Spine biologics market: Surgery market share analysis, 2024 & 2030
  • Fig. 22 Anterior cervical discectomy and fusion (ACDF) market, 2018 - 2030 (USD Billion)
  • Fig. 23 Transforaminal lumbar interbody fusion (TLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 24 Posterior lumbar interbody fusion (PLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 25 Anterior lumbar interbody fusion (ALIF) market, 2018 - 2030 (USD Billion)
  • Fig. 26 Lateral lumbar interbody fusion (LLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 27 Spine biologics market: End use segment dashboard
  • Fig. 28 Spine biologics market: End use market share analysis, 2024 & 2030
  • Fig. 29 Hospitals market, 2018 - 2030 (USD Billion)
  • Fig. 30 Outpatient facilities market, 2018 - 2030 (USD Billion)
  • Fig. 31 Spine biologics market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 40 Europe spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 57 Asia Pacific spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 70 Latin America spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 75 MEA spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework